-
-
-
-
-
-
-
Biohaven Reports Fourth Quarter and Full Year 2022 Financial Results and Reports Recent Business Developments
-
-
-
-
-
-
-
Biohaven Sets New Course with $258 Million in Cash, a Proven Team and Deep Pipeline to Continue its Journey to Advance Science for Patients
-
-
-
-
-
-
-
Portage Biotech (PRTG) Acquires Remaining 22% Stake in Invariant Natural Killer T cell (iNKT) Agonist Platform
-
-
-
-
-
-
-
BHVN Alert: Monsey Firm of Wohl & Fruchter LLP Investigating Sale of Biohaven Pharmaceutical to Pfizer
-
-
-
-
-
-
923,561 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All